Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Study Summary

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions / Drugs

Pumitamig Atezolizumab Etoposide Carboplatin (or cisplatin if carboplatin is not tolerated)

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment621 participants

Primary Completion—

Lead SponsorBioNTech SE

Data Retrieved2026-04-11 02:55:25.057564+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.